+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 110 Pages
  • November 2024
  • GlobalData
  • Astrazeneca PLC
  • ID: 1314893
AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

AstraZeneca Plc (AstraZeneca) is a biopharmaceutical company, that focuses on the discovery, production, and commercialization of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa, and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

AstraZeneca Plc Key Recent Developments

  • Nov 12, 2024: AstraZeneca Invests $3.5 billion in R&D and Manufacturing in the United States
  • Nov 07, 2024: AstraZeneca showcases strength of haematology portfolio and pipeline at ASH 2024
  • Oct 14, 2024: ENHERTU gains conditional approval in China to treat NSCLC
  • Oct 10, 2024: Alexion, AstraZeneca Rare Disease data at the 2024 AANEM Annual Meeting and MGFA Scientific Session further demonstrate advancement in gMG care

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • AstraZeneca Plc - Key Facts
  • AstraZeneca Plc - Key Employees
  • AstraZeneca Plc - Key Employee Biographies
  • AstraZeneca Plc - Major Products and Services
  • AstraZeneca Plc - History
  • AstraZeneca Plc - Company Statement
  • AstraZeneca Plc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • AstraZeneca Plc - Business Description
  • Other Break-up: Alliance Revenue
  • Performance
  • Other Break-up: Collaboration Revenue
  • Overview
  • Performance
  • Other Break-up: Product Sales
  • Overview
  • Performance
  • Geographical Segment: Australia
  • Performance
  • Geographical Segment: Canada
  • Performance
  • Geographical Segment: China
  • Performance
  • Geographical Segment: France
  • Performance
  • Geographical Segment: Germany
  • Performance
  • Geographical Segment: Italy
  • Performance
  • Geographical Segment: Japan
  • Performance
  • Geographical Segment: Others
  • Performance
  • Geographical Segment: Spain
  • Performance
  • Geographical Segment: Sweden
  • Performance
  • Geographical Segment: UK
  • Performance
  • Geographical Segment: US
  • Performance
  • R&D Overview
  • AstraZeneca Plc - Corporate Strategy
  • AstraZeneca Plc - SWOT Analysis
  • SWOT Analysis - Overview
  • AstraZeneca Plc - Strengths
  • AstraZeneca Plc - Weaknesses
  • AstraZeneca Plc - Opportunities
  • AstraZeneca Plc - Threats
  • AstraZeneca Plc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • AstraZeneca Plc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Nov 12, 2024: AstraZeneca Invests $3.5 billion in R&D and Manufacturing in the United States
  • Nov 07, 2024: AstraZeneca showcases strength of haematology portfolio and pipeline at ASH 2024
  • Oct 14, 2024: ENHERTU gains conditional approval in China to treat NSCLC
  • Oct 10, 2024: Alexion, AstraZeneca Rare Disease data at the 2024 AANEM Annual Meeting and MGFA Scientific Session further demonstrate advancement in gMG care
  • Sep 16, 2024: New Collaboration to Introduce Liquid Biopsy Testing for Lung Cancer
  • Sep 14, 2024: SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024
  • Sep 03, 2024: AstraZeneca Advances Ambition to Improve Standards of Care in Multiple Cancer Types at WCLC and ESMO 2024
  • Aug 08, 2024: Conduit acquires three first-in-class assets from AstraZeneca
  • Jul 25, 2024: AstraZeneca Releases Half-Year Report
  • Jul 01, 2024: Aptamer Group Signs New Agreement With AstraZeneca
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • AstraZeneca Plc, Key Facts
  • AstraZeneca Plc, Key Employees
  • AstraZeneca Plc, Key Employee Biographies
  • AstraZeneca Plc, Major Products and Services
  • AstraZeneca Plc, History
  • AstraZeneca Plc, Subsidiaries
  • AstraZeneca Plc, Joint Venture
  • AstraZeneca Plc, Key Competitors
  • AstraZeneca Plc, Ratios based on current share price
  • AstraZeneca Plc, Annual Ratios
  • AstraZeneca Plc, Interim Ratios
  • AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • AstraZeneca Plc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • AstraZeneca Plc, Performance Chart (2019 - 2023)
  • AstraZeneca Plc, Ratio Charts
  • AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Takeda Pharmaceutical Co Ltd
  • Sanofi
  • Pfizer Inc
  • Novartis AG
  • Merck & Co Inc
  • Johnson & Johnson
  • GSK plc
  • Gilead Sciences Inc
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Co
  • Daiichi Sankyo Co Ltd
  • Bristol-Myers Squibb Co
  • Astellas Pharma Inc
  • Amgen Inc
  • AbbVie Inc